Detection of (1, 3)-β-d-glucan in bronchoalveolar lavage and serum samples collected from immunocompromised hosts

Mycopathologia

Volumn 175, Issue 1-2, 2013, Pages 33-41

  Theel, Elitza S ^a   Jespersen, Deborah J ^a   Iqbal, Seher ^a   Bestrom, Jean E ^a   Rollins, Leonard O ^a   Misner, Lori J ^a   Markley, Barbara J ^b   Mandrekar, Jayawant ^a   Baddour, Larry M ^a   Limper, Andrew H ^a   Wengenack, Nancy L ^a   Binnicker, Matthew J ^a  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

(1,3) d Glucan; BAL; ICH; Serum

Indexed keywords

ASPERGILLUS; CANDIDA; FUNGI; PNEUMOCYSTIS;

EID: 84872773740     PISSN: 0301486X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11046-012-9579-y     Document Type: Article

References (35)

1. Cuenca-Estrella M, Bernal-Martinez L, Buitrago MJ, Castelli MV, Gomez-Lopez A, Zaragoza O, et al. Update on the epidemiology and diagnosis of invasive fungal infection. Int J Antimicrob Agents. 2008; 32(Suppl 2): S143-7.
2. Clark TA, Hajjeh RA. Recent trends in the epidemiology of invasive mycoses. Curr Opin Infect Dis. 2002; 15(6): 569-74.
3. Odabasi Z, Mattiuzzi G, Estey E, Kantarjian H, Saeki F, Ridge RJ, et al. Beta-d-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis. 2004; 39(2): 199-205.
4. Erjavec Z, Kluin-Nelemans H, Verweij PE. Trends in invasive fungal infections, with emphasis on invasive aspergillosis. Clin Microbiol Infect. 2009; 15(7): 625-33.
5. Pickering JW, Sant HW, Bowles CA, Roberts WL, Woods GL. Evaluation of a (1→3)-β-d-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol. 2005; 43(12): 5957-62.
6. Miceli MH, Lee SA. Emerging moulds: epidemiological trends and antifungal resistance. Mycoses 2011.
7. Miceli MH, Diaz JA, Lee SA. Emerging opportunistic yeast infections. Lancet Infect Dis. 2011; 11(2): 142-51.
8. Mikolajewska A, Schwartz S, Ruhnke M. Antifungal treatment strategies in patients with haematological diseases or cancer: from prophylaxis to empirical, pre-emptive and targeted therapy. Mycoses. 2011.
9. Jones BL, McLintock LA. Impact of diagnostic markers on early antifungal therapy. Curr Opin Infect Dis. 2003; 16(6): 521-6.
10. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother. 2005; 49(9): 3640-5.
11. Limper AH, Knox KS, Sarosi GA, Ampel NM, Bennett JE, Catanzaro A, et al. An official american thoracic society statement: treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med. 2011; 183(1): 96-128.
12. Paterson DL, Singh N. Invasive Aspergillosis in transplant recipients. Medicine (Baltimore). 1999; 78(2): 123-38.
13. Singh N, Paterson DL. Aspergillus infections in transplant recipients. Clin Microbiol Rev. 2005; 18(1): 44-69.
14. Ahmad S, Khan ZU, Theyyathel AM. Diagnostic value of DNA, (1-3)-β-d-glucan, and galactomannan detection in serum and bronchoalveolar lavage of mice experimentally infected with Aspergillus terreus. Diagn Microbiol Infect Dis. 2007; 59(2): 165-71.
15. Held J, Koch MS, Reischl U, Danner T, Serr A. Serum (1→3)-beta-d-glucan measurement as an early indicator of Pneumocystis jirovecii pneumonia and evaluation of its prognostic value. Clin Microbiol Infect. 2011; 17(4): 595-602.
16. Posteraro B, Torelli R, De Carolis E, Posteraro P, Sanguinetti M. Update on the laboratory diagnosis of invasive fungal infections. Mediterr J Hematol Infect Dis 2011; 3.
17. Pazos C, Ponton J, Del Palacio A. Contribution of (1→3)-β-d-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan. J Clin Microbiol. 2005; 43(1): 299-305.
18. Karageorgopoulos DE, Vouloumanou EK, Ntziora F, Michalopoulos A, Rafailidis PI, Falagas ME. Beta-d-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin Infect Dis. 2011; 52(6): 750-70.
19. Ostrosky-Zeichner L, Alexander BD, Kett DH, Vazquez J, Pappas PG, Saeki F, et al. Multicenter clinical evaluation of the (1→3) beta-d-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis. 2005; 41(5): 654-9.
20. Khan ZU, Ahmad S, Theyyathel AM. Diagnostic value of DNA and (1→3)-β-d-glucan detection in serum and bronchoalveolar lavage of mice experimentally infected with Fusarium oxysporum. J Med Microbiol. 2008; 57: 36-42.
21. Arcenas RC, Uhl JR, Buckwalter SP, Limper AH, Crino D, Roberts GD, et al. A real-time polymerase chain reaction assay for detection of Pneumocystis from bronchoalveolar lavage fluid. Diagn Microbiol Infect Dis. 2006; 54(3): 169-75.
22. Wilson JW, Limper AH, Grys TE, Karre T, Wengenack NL, Binnicker MJ. Pneumocystis jirovecii testing by real-time polymerase chain reaction and direct examination among immunocompetent and immunosuppressed patient groups and correlation to disease specificity. Diagn Microbiol Infect Dis. 2011; 69(2): 145-52.
23. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008; 46(12): 1813-21.
24. Mennink-Kersten MA, Ruegebrink D, Verweij PE. Pseudomonas aeruginosa as a cause of 1, 3-beta-d-glucan assay reactivity. Clin Infect Dis. 2008; 46(12): 1930-1.
25. Heyland D, Jiang X, Day AG, Laverdiere M. Serum beta-d-glucan of critically ill patients with suspected ventilator-associated pneumonia: preliminary observations. J Crit Care 2011.
26. Shahid Z, Kumar NS, Restrepo A, Haider S, Muzaffar J, Grazziutii M et al. Elevated serum β-d-glucan (BDG) as a marker for chemotherapy-induced mucosal barrier injury (MBI) in adults with hematologic malignancies: a retrospective analysis. 2011.
27. Ishizuka Y, Tsukada H, Gejyo F. Interference of (1→3)-β-d-glucan administration in the measurement of plasma (1→3)-β-d-glucan. Intern Med. 2004; 43(2): 97-101.
28. Viscoli C, Machetti M, Cappellano P, Bucci B, Bruzzi P, van Lint MT, et al. False-positive galactomannan platelia Aspergillus test results for patients receiving piperacillin-tazobactam. Clin Infect Dis. 2004; 38(6): 913-6.
29. Damiani C, Le Gal S, Lejeune D, Brahimi N, Virmaux M, Nevez G, et al. Serum (1→3)-β-d-glucan levels in primary infection and pulmonary colonization with Pneumocystis jirovecii. J Clin Microbiol. 2011; 49(5): 2000-2.
30. Desmet S, van Wijngaerden E, Maertens J, Verhaegen J, Verbeken E, De Munter P, et al. Serum (1-3)-β-d-glucan as a tool for diagnosis of Pneumocystis jirovecii pneumonia in patients with human immunodeficiency virus infection or hematological malignancy. J Clin Microbiol. 2009; 47(12): 3871-4.
31. Sax PE, Komarow L, Finkelman MA, Grant PM, Andersen J, Scully E, et al. Blood (1→3)-β-d-glucan as a diagnostic test for HIV-related Pneumocystis jirovecii pneumonia. Clin Infect Dis. 2011; 53(2): 197-202.
32. Marty FM, Koo S, Bryar J, Baden LR. (1→3) β-d-glucan assay positivity in patients with Pneumocystis (carinii) jirovecii pneumonia. Ann Intern Med 2007; 147(1).
33. Akamatsu N, Sugawara Y, Kaneko J, Tamura S, Makuuchi M. Preemptive treatment of fungal infection based on plasma (1→3) β-d-glucan levels after liver transplantation. Infection. 2007; 35(5): 346-51.
34. Presterl E, Parschalk B, Bauer E, Lassnigg A, Hajdu S, Graninger W. Invasive fungal infections and (1, 3)-β-d-glucan serum concentrations in long-term intensive care patients. Int J Infect Dis. 2009; 13(6): 707-12.
35. Lamoth F, Cruciani M, Mengoli C, Castagnola E, Lortholary O, Richardson M, et al. beta-glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the third European Conference on Infections in Leukemia (ECIL-3). Clin Infect Dis. 2012; 54(5): 633-43.